Septerna raises $150m in Series B funding round
2023-07-12
蛋白降解靶向嵌合体
Preview
来源: Pharmaceutical Technology
A PTH1R agonistPTH1R agonist programme of Septerna is being developed to treat hypoparathyroidism. Credit: Kateryna Kon via Shutterstock.com.
Biotechnology firm Septerna has raised $150m in a Series B funding round to develop its pipeline of new oral small molecule therapies that act on G protein-coupled receptors (GPCRs).
New investor RA Capital Management led the round, with current investors Third Rock Ventures, Invus, Catalio Capital Management, Samsara BioCapital and BVF Partners among others taking part.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Triplex in Myelofibrosis GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - AVID-200 in Myelofibrosis GlobalData
View allCompanies IntelligenceSamsara BioCapital LLCThird Rock Ventures LLCRA Capital Management LPBVF Partners LPCatalio Capital Management LPView all
RA Capital Management partner Jake Simson will join the board of directors of Septerna.
The proceeds will be utilised for portfolio development and to progress its lead parathyroid hormone 1 receptor (PTH1R) programme to clinical proof-of-mechanism.
This PTH1R agonistPTH1R agonist programme is being developed to treat hypoparathyroidism, a condition marked by reduced levels of PTH.
The company will also use the funds to advance the preclinical development of a second thyroid-stimulating hormone receptor-targeting programme and other initial-stage assets.
“This is an exciting time for GPCR drug development, and we are eager to move our novel products toward clinical development.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。